10.47
-0.31 (-2.88%)
| Previous Close | 10.78 |
| Open | 10.80 |
| Volume | 49,011 |
| Avg. Volume (3M) | 98,583 |
| Market Cap | 269,893,568 |
| Price / Sales | 11.15 |
| Price / Book | 1.56 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.360 |
| Total Debt/Equity (MRQ) | 0.29% |
| Current Ratio (MRQ) | 37.06 |
| Operating Cash Flow (TTM) | -33.35 M |
| Levered Free Cash Flow (TTM) | -22.27 M |
| Return on Assets (TTM) | -15.32% |
| Return on Equity (TTM) | -20.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Contineum Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.19% |
| % Held by Institutions | 72.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Versant Venture Management, Llc | 30 Sep 2024 | 918,163 |
| Sectoral Asset Management Inc | 30 Sep 2024 | 800,887 |
| 52 Weeks Range | ||
| Median | 31.00 (196.08%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 09 Jan 2025 | 31.00 (196.08%) | Buy | 13.37 |
| 07 Nov 2024 | 31.00 (196.08%) | Buy | 18.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) |
| 16 Dec 2024 | Announcement | Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 |
| 25 Nov 2024 | Announcement | Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference |
| 18 Nov 2024 | Announcement | Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain |
| 13 Nov 2024 | Announcement | Contineum Therapeutics to Attend Upcoming Investor Conferences |
| 06 Nov 2024 | Announcement | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |